Eagle Pharmaceuticals (EGRX) Rating Increased to Strong-Buy at BidaskClub

BidaskClub upgraded shares of Eagle Pharmaceuticals (NASDAQ:EGRX) from a buy rating to a strong-buy rating in a research note published on Saturday morning.

A number of other equities analysts have also weighed in on EGRX. ValuEngine raised shares of Eagle Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, May 11th. Mizuho reissued an underperform rating and issued a $54.00 price objective on shares of Eagle Pharmaceuticals in a research report on Thursday, May 17th. Piper Jaffray Companies reissued a buy rating and issued a $79.00 price objective on shares of Eagle Pharmaceuticals in a research report on Tuesday, January 30th. Zacks Investment Research lowered shares of Eagle Pharmaceuticals from a hold rating to a strong sell rating in a research report on Thursday, March 1st. Finally, Royal Bank of Canada set a $71.00 price objective on shares of Eagle Pharmaceuticals and gave the company a buy rating in a research report on Monday, February 26th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $68.00.

Eagle Pharmaceuticals opened at $66.53 on Friday, Marketbeat Ratings reports. The company has a quick ratio of 5.66, a current ratio of 5.87 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $969.64 million, a PE ratio of 19.74 and a beta of 1.39. Eagle Pharmaceuticals has a 1-year low of $45.05 and a 1-year high of $84.20.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings data on Thursday, May 10th. The specialty pharmaceutical company reported $0.53 earnings per share for the quarter, missing analysts’ consensus estimates of $0.68 by ($0.15). The firm had revenue of $46.60 million during the quarter, compared to analyst estimates of $48.88 million. Eagle Pharmaceuticals had a net margin of 15.32% and a return on equity of 21.89%. The business’s quarterly revenue was down 39.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.42 EPS. research analysts anticipate that Eagle Pharmaceuticals will post 1.92 earnings per share for the current fiscal year.

In related news, Director Sander A. Flaum sold 2,340 shares of the company’s stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $53.94, for a total transaction of $126,219.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 19.50% of the company’s stock.

A number of hedge funds have recently modified their holdings of EGRX. Wells Fargo & Company MN increased its position in Eagle Pharmaceuticals by 35.5% during the third quarter. Wells Fargo & Company MN now owns 21,506 shares of the specialty pharmaceutical company’s stock worth $1,283,000 after purchasing an additional 5,640 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in Eagle Pharmaceuticals by 10.5% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 67,094 shares of the specialty pharmaceutical company’s stock worth $3,585,000 after purchasing an additional 6,378 shares during the last quarter. Bowling Portfolio Management LLC acquired a new position in Eagle Pharmaceuticals during the fourth quarter worth approximately $1,806,000. Fisher Asset Management LLC increased its position in Eagle Pharmaceuticals by 24.5% during the fourth quarter. Fisher Asset Management LLC now owns 29,784 shares of the specialty pharmaceutical company’s stock worth $1,591,000 after purchasing an additional 5,863 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in Eagle Pharmaceuticals by 63.7% during the fourth quarter. SG Americas Securities LLC now owns 7,385 shares of the specialty pharmaceutical company’s stock worth $395,000 after purchasing an additional 2,874 shares during the last quarter.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply